Particle size variability impacts performance during supplier change – inspection questions regulators ask


Published on 24/04/2026

How Particle Size Variability Affects Performance Following Supplier Changes

The pharmaceutical industry frequently encounters the challenge of maintaining consistent product quality during supplier changes, especially regarding raw materials like Active Pharmaceutical Ingredients (APIs) and excipients. Particle size variability is a critical factor that can significantly affect a product’s performance, leading to drug efficacy and safety issues. This article delves into the structured approach to investigate particulate size variability post-supplier change, encompassing signal identification, investigative methods, and corrective actions.

After reading this article, pharmaceutical professionals will better understand how to effectively investigate particle size variability issues, implement corrective actions, and ensure production processes remain compliant with regulatory standards established by agencies such as the FDA, EMA, and MHRA.

Symptoms/Signals on the Floor or in the Lab

Identifying symptoms of particle size variability early is crucial for effective investigation and resolution. Key symptoms might include:

  • Variability in dosage form characteristics, such as dissolution rates and flowability in powder blends.
  • Increased batch failures or out-of-specification (OOS) results,
particularly in dissolution testing.
  • Inconsistent product performance leading to unexpected side effects or efficacy issues.
  • Complaints from quality control (QC) regarding unexpected results trending outside typical acceptance criteria.
  • Elevated variability in stability studies indicating potential compatibility issues with excipients.
  • These signals can indicate underlying issues with raw material quality, especially when transitioning to a new supplier. Regular monitoring and thorough documentation are vital in capturing these phenomena.

    Likely Causes

    When investigating particle size variability, it’s essential to categorize likely causes to streamline the focus of the investigation. The major categories include:

    Category Likely Causes
    Materials Variability in supplier raw materials due to different manufacturing processes.
    Method Differences in testing methods or sampling techniques used for particle size analysis.
    Machine Variability introduced by different equipment settings or conditions during processing.
    Man Operator variability in handling processes or malfunction of equipment.
    Measurement Inaccurate measurements due to calibration issues or method validation failures.
    Environment Changes in environmental conditions affecting raw material behavior during storage or processing.

    Each potential cause must be assessed based on its relevance to the observed symptoms, keeping a focus on materials received from the new supplier.

    Immediate Containment Actions (First 60 Minutes)

    Swift action is necessary to contain deviations related to particle size variability. Initial actions should include:

    • Quarantine affected materials to prevent further processing until a full assessment is performed.
    • Initiate an investigation team consisting of QA, QC, and Operations personnel to begin assessing the situation.
    • Document all findings and actions taken, ensuring traceability for audit readiness.
    • Evaluate any changes made to the supplier and gather relevant material specifications, Certificates of Analysis (CoA), and change notifications.
    • Conduct a rapid assessment of any recently produced batches that utilized the newly sourced materials; this includes sample testing for particle size distribution.

    Proper containment sets the stage for a thorough investigation and minimizes the risk of further complications.

    Investigation Workflow

    Establishing a structured investigation workflow is critical for identifying and mitigating root causes effectively. The workflow should consist of the following steps:

    1. Data Collection:
      • Collect batch records, supplier materials, and QC results.
      • Review specifications from the new supplier and compare them to historical data from previous suppliers.
      • Analyze particle size distribution data across batches both pre- and post-supplier change.
    2. Data Interpretation:
      • Identify patterns in variabilities—compare new data against historical baselines.
      • Assess trends in quality control results, focusing on outliers and shifts in performance.
    3. Hypothesis Generation:
      • Generate hypotheses based on observed data trends that could link the observed symptoms to potential causes.
    4. Testing of Hypotheses:
      • Design experiments or additional tests focused on evaluating hypotheses derived from the data.

    This structured approach ensures that the investigation remains focused and that all relevant factors are considered for root cause analysis.

    Root Cause Tools

    Different root cause analysis tools can be beneficial based on the complexity of the issues; the following are commonly used:

    • 5 Why Analysis: Effective for straightforward problems where causes are historically well-understood. It involves repeatedly asking “Why” to peel back layers of symptoms until reaching a root cause.
    • Fishbone Diagram (Ishikawa): A visual tool that helps categorize and systematically explore multiple potential causes across the ‘5Ms’ (Man, Machine, Method, Materials, Measurement).
    • Fault Tree Analysis (FTA): More complex issues may warrant this deductive approach to analyze the probability of different failure paths contributing to the problem, which is particularly useful in a multifaceted production environment.

    Selecting the appropriate tool depends on the nature of the variability issues and the depth required for root cause identification.

    CAPA Strategy

    Once root cause analysis is complete, it’s vital to implement a comprehensive Corrective and Preventive Action (CAPA) strategy. The strategy should include:

    • Correction: This should address the immediate containment of the issue, e.g., discarding affected batches and discussing consequences with involved stakeholders.
    • Corrective Action: Based on root causes identified, develop action items customized for each cause, such as enhancing supplier audits, adjusting manufacturing parameters, or refining testing methodologies.
    • Preventive Action: Long-term strategies may involve implementing additional robustness checks in supplier evaluations, revising acceptance criteria, or initiating ongoing monitoring of particle size distributions.

    Documentation is critical at each step, allowing you to track performance and further refine processes as necessary.

    Related Reads

    Control Strategy & Monitoring

    Effective control strategies and ongoing monitoring are essential for sustaining product quality and consistency in light of supplier changes. Key components of a control strategy should include:

    • Statistical Process Control (SPC): Utilize SPC charts for critical quality attributes (CQAs) relevant to particle size to detect deviations from established processes.
    • Sampling Plans: Implement rigorous and representative sampling plans for testing incoming materials, especially during the initial transition period.
    • Alarms and Alerts: Consider establishing alarm thresholds for particle size measurements to trigger analysis if deviations are detected in real-time.
    • Verification Mechanisms: Ensure regular validation of measurement instruments and reliability of measurement methods.

    This systematic control strategy can create a safety net that ensures early identification of issues stemming from supplier changes.

    Validation / Re-qualification / Change Control Impact

    Changes to suppliers necessitate a detailed review of validation, re-qualification, and change control processes:

    • Conduct a thorough evaluation of how the change in suppliers might affect current validations and ensure compatibility with existing processes.
    • Re-qualify affected processes where necessary, focusing particularly on critical processing stages that may be impacted by particle size variability.
    • Engage in change control activities to record all updates comprehensively along with rationale, enhancing transparency and compliance with regulatory expectations.

    These steps are vital to ensuring that the quality and performance of the pharmaceutical product remain consistent and reliable.

    Inspection Readiness: What Evidence to Show

    Regulatory inspections require robust documentation to demonstrate compliance and readiness in addressing particle size variability issues. Essential records include:

    • Batch Records: Well-maintained records detailing production processes, deviations, and corrective actions taken as a result of variabilities detected.
    • Logs: Comprehensive logs capturing routine monitoring data, testing results, and any adjustments made to the processes.
    • Deviation Reports: Documenting any OOS results with detailed analyses, conclusions, and actions leading to resolution.
    • Supplier Audits: Results of audits conducted on new suppliers focusing on material quality and consistency.

    Preparing thorough documentation facilitates smoother inspection outcomes and demonstrates a commitment to quality assurance.

    FAQs

    What should be my first step if I encounter particle size variability?

    Immediately quarantine affected materials and initiate an investigation to understand the extent of the issue.

    How can I verify the consistency of new materials from suppliers?

    Conduct rigorous testing using established methods and compare results against historical data to establish a baseline.

    What tools are best suited for root cause analysis in this context?

    The 5-Why, Fishbone Diagram, and Fault Tree Analysis are effective tools, depending on the complexity of the issue.

    What kind of training should staff undergo regarding new suppliers?

    Staff should be trained in supplier quality assurance standards, understanding acceptance criteria, and the importance of maintaining quality during supplier changes.

    How often should batch records be reviewed for compliance?

    Batch records should be reviewed every time a new batch is produced or when there are changes in the materials or processes involved.

    What documentation is critical during inspections?

    Critical documentation includes batch records, logs, deviation reports, and results from quality control tests.

    When do I need to conduct re-validation after a supplier change?

    Re-validation is necessary when there are significant changes that might impact the product performance, such as changes in raw material supplier.

    How can I ensure long-term consistency from a new supplier?

    Implement a robust supplier management system that includes regular audits, testing, and monitoring of incoming materials over time.

    Pharma Tip:  Polymorphic form inconsistency during deviation investigation – root cause investigation framework